Hallmark microRNA signature in liquid biopsy identifies hepatocellular carcinoma and differentiates it from liver metastasis
Victor Chun-Lam Wong, Ming-In Wong, Chi-Tat Lam, Maria Li Lung, Ka On Lam, Victor Ho-Fun Lee · Journal of Cancer · 2021
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2021
Abstract
Purpose: This study aims to develop a liquid biopsy assay to identify HCC and differentially diagnose hepatocellular carcinoma (HCC) from colorectal carcinoma (CRC) liver metastasis.Methods: Thirty-two microRNAs ("HallMark-32" panel) were designed to target the ten cancer hallmarks in HCC.Quantitative PCR and supervised machine learning models were applied to develop an HCC-specific diagnostic model.One hundred thirty-three plasma samples from intermediate-stage HCC patients, colorectal cancer (CRC) patients with liver metastasis, and healthy individuals were examined.Results: Six differentially expressed microRNAs ("Signature-Six" panel) were identified after comparing HCC and healthy individuals.The microRNA miR-221-3p, miR-223-3p, miR-26a-5p, and miR-30c-5p were significantly down-regulated in the plasma of HCC samples, while miR-365a-3p and miR-423-3p were significantly up-regulated.Machine learning models combined with HallMark-32 and Signature-Six panels demonstrated promising performance with an AUC of 0.85-0.96(p ≤ 0.018) and 0.84-0.93(p ≤ 0.021), respectively.Further modeling improvement by adjusting sample quality variation in the HallMark-32 panel boosted the accuracy to 95% ± 0.01 and AUC to 0.991 (95% CI 0.96-1, p = 0.001), respectively.Even in alpha fetoprotein (AFP)-negative (< 20ng/mL) HCC samples, HallMark-32 still achieved 100% sensitivity in identifying HCC.The Cancer Genome Atlas (TCGA, n=372) analysis demonstrated a significant association between HallMark-32 and HCC patient survival.Conclusion: To the best of our knowledge, this is the first report to utilize circulating miRNAs and machine learning to differentiate HCC from CRC liver metastasis.In this setting, HallMark-32 and Signature-Six are promising non-invasive tests for HCC differential diagnosis and distinguishing HCC from healthy individuals.
Open the resolved locator · 10.7150/jca.59933
Metadata licence: OpenAlex metadata (CC0)